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Abstract
Introduction:  Use  of  non-steroidal  anti-inﬂammatory  drugs  (NSAIDs)  has  increased  over  the  last
few years  and  identiﬁcation  of  gastrointestinal  risk  factors  is  a  key  factor  for  prevention  of  its
complications.  Even  after  correct  identiﬁcation  of  those  risk  factors,  only  a  small  percentage
of Family  Physicians  prescribe  gastroprotection.
Aims:  To  knowledge  gastrointestinal  risk  factors  and  gastroprotection’s  prescription  by  Family
Physicians  in  patients  receiving  NSAIDs.
Methods:  Observational,  cross-sectional,  random  sample  study,  using  a  survey  among  300  Family
Physicians,  performed  in  2007.  Questions  were  asked  about  perceived  patients  rates  or  hypo-
thetical scenarios  and  answers  were  valued  on  an  intention-to-treat  basis.  The  main  outcome
measure was  the  gastroprotection’s  prescription  rate  among  patients  taking  NSAIDs.
Results: The  perceived  proportion  of  patients  receiving  NSAIDs  was  38%  and  from  these,  40%
were taking  gastroprotective  drugs.  The  main  identiﬁed  gastrointestinal  risk  factors  were:  com-
plicated peptic  ulcer  (98%),  age  ≥  65  years  (96%),  smoking  habits  and  alcohol  consumption
(96%), dyspepsia  (95%),  high-doses  of  NSAIDs  (94%),  corticosteroids  co-administration  (91%)  and
consumption  of  two  or  more  NSAIDs  (90%).  Gastroprotection  would  be  prescribed  in  82%  of
patients with  history  of  complicated  peptic  ulcer;  60%  if  receiving  two  or  more  or  a  high  dose
of NSAIDs;  53%  if  with  Helicobacter  pylori  infection  and  51%  if  aged  ≥  65  years.  For  all  risk
factors, gastroprotection  use  would  be  only  of  47.3%  (95%  conﬁdence  interval:  45.6--49.0%).
Conclusions:  Family  Physicians  are  aware  of  NSAIDs’  gastrointestinal  toxicity  but  risk  estimation
seems inadequate  since  they  will  not  prescribe  gastrointestinal  protection  in  more  than  half
the cases.
©  2012  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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PALAVRAS  CHAVE
Anti-inﬂamatórios
não
esteroides/efeitos
secundários;
Aspirina/efeitos
secundários;
Úlcera
péptica/prevenc¸ão  e
tratamento;
Fatores  de  risco;
Cuidados  de  Saúde
Primários
Uso  de  anti-inﬂamatórios  não  esteroides  e  ausência  de  prescric¸ão  de  gastroprotec¸ão
por  médicos  de  medicina  geral  e  familiar:  resultados  de  um  inquérito
Resumo
Introduc¸ão:  O  uso  de  Anti-Inﬂamatórios  Não  Esteroides  (AINE)  tem  aumentado  nos  últimos  anos
e a  identiﬁcac¸ão  de  fatores  de  risco  gastrointestinal  é  fundamental  para  a  prevenc¸ão  de  suas
complicac¸ões. Mesmo  após  a  correta  identiﬁcac¸ão  desses  fatores  de  risco,  apenas  uma  pequena
percentagem  dos  médicos  de  Medicina  Geral  e  Familiar  efetuam  gastroprotec¸ão.
Objetivos:  Conhecimento  dos  fatores  de  risco  gastrointestinais  e  prescric¸ão  de  gastroprotec¸ão
por médicos  de  Medicina  Geral  e  Familiar  em  pacientes  que  tomam  AINE.
Métodos:  Estudo  observacional,  transversal,  por  amostra  aleatória,  por  meio  de  um  inquérito
a 300  médicos  de  Medicina  Geral  e  Familiar,  realizado  em  2007.  Foram  efetuadas  perguntas
sobre as  taxas  de  pacientes  esperadas  ou  cenários  hipotéticos  e  as  respostas  foram  avaliadas
com base  na  intenc¸ão  de  tratar.  A  principal  variável  de  resultado  foi  a  taxa  de  prescric¸ão  de
gastroprotec¸ão em  pacientes  medicados  com  AINE.
Resultados:  A  proporc¸ão  de  pacientes  medicados  com  AINE  foi  de  38%  e,  destes,  40%  estavam
a efetuar  gastroprotec¸ão.  Os  principais  fatores  de  risco  gastrointestinais  identiﬁcados  foram:
úlcera péptica  complicada  (98%),  idade  ≥  65  anos  (96%),  tabagismo  e  consumo  de  álcool  (96%),
dispepsia (95%),  alta  dose  de  AINE  (94%),  coadministrac¸ão  de  corticosteroides  (91%)  e  uso
simultâneo  de  2  ou  mais  AINE  (90%).  Seria  prescrita  gastroprotec¸ão  em  82%  dos  pacientes  com
história de  úlcera  péptica  complicada,  60%  se  recebessem  2  ou  mais  AINE  ou  um  AINE  mas  em
dose elevada,  em  53%  se  houvesse  infec¸ão  por  Helicobacter  pylori  e  em  51%  se  idade  ≥  65
anos. Para  todos  os  fatores  de  risco,  o  uso  de  gastroprotec¸ão  seria  de  apenas  47,3%  (intervalo
de conﬁanc¸a  a  95%:  45,6--49,0%).
Conclusões:  Os  médicos  de  Medicina  Geral  e  Familiar  estão  conscientes  da  toxicidade  gastroin-
testinal dos  AINE,  mas  a  sua  estimativa  do  risco  parece  inadequada,  uma  vez  que  não  planeiam
prescrever protec¸ão  gastrointestinal  em  mais  da  metade  dos  casos  necessários.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos  reservados.
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on-steroidal  anti-inﬂammatory  drugs’  (NSAIDs)  use,  includ-
ng  acetylsalicylic  acid  (ASA),  has  been  increasing  over  the
ast  years,  being  amongst  the  most  commonly  prescribed  and
sed  drugs.  A  study  conducted  in  Portugal  showed  that  the
ost  prescribed  therapeutic  class  by  Family  Physicians  was
SAIDs  totalling  8.2%,  while  ASA  and  derivatives  represented
.3%  of  all  medicines.1 Other  studies  in  Portugal  showed  that
SAIDs,  analgesics  and  antipyretic  drugs  rank  as  ﬁfth  among
he  chronically  used  medicines,  being  used  by  12--15%  of  the
tudied  users.2
NSAIDs  are  highly  effective  agents;  however,  its  use  is
ssociated  to  adverse  events,  especially  gastrointestinal.
SAIDs-related  adverse  events  accounted  for  11%  of  the
eports  received  by  the  Portuguese  Drug  Prescription  Vig-
lance  System  between  1993  and  2002  and  gastrointestinal
omplications  represented  19%  of  the  overall  reports.  Severe
dverse  reactions  to  NSAIDs,  which  represented  more  than
0%  of  the  reports,  caused  hospitalization  in  31%  of  the
ases.3
NSAIDs  induced  gastrointestinal  complications  are  a  pub-
ic  health  concern4 and  the  appropriate  identiﬁcation  and
valuation  of  gastrointestinal  risk  factors  associated  to
SAIDs  use  in  each  and  every  patient  as  well  as  the
oncomitant  use  of  gastrointestinal  protective  agents,  if
ppropriate,  are  highly  effective  preventive  strategies.5 To
he  best  of  our  knowledge,  there  are  no  published  clinical
a
b
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ttudies  carried  out  in  the  Portuguese  population,  evaluating
oth  the  prescription  of  gastroprotective  agents  in  patients
eceiving  NSAIDs  and  the  inﬂuence  of  gastrointestinal  risk
actors  in  this  prescription  at  a  Primary  Care  setting,  with
nly  one  published  study  that  evaluated  the  gastroprotec-
ion  use  among  NSAIDs  admissions  using  hospital  records  in
 Tertiary  Care  setting.6
The  aim  of  this  study  was  to  feature  Family  Physicians’
linical  practice  in  Portugal,  regarding  both  the  identiﬁca-
ion  of  gastrointestinal  risks  and  the  prevention  of  NSAIDs
omplications,  namely  the  recognition  of  gastrointestinal
omplications’  risk  factors  and  the  impact  of  those  risk  fac-
ors  in  the  decision  of  prescribing  gastroprotective  therapy.
aterials and methods
tudy  sample
bservational,  cross-sectional  study,  conducted  according
o  methods  generally  used  for  research  interview-based
tudies  using  a  random  sample.  The  study  population
onsisted  of  Family  Physicians  registered  in  Districts  from
he  north  (Porto),  centre  (Coimbra),  south  (Faro/Portimão)
nd  the  capital  city  of  Portugal  (Lisbon).  Prime  Focus  (Lis-
on,  Portugal),  a  specialized  company  in  Market  Research
tudies,  provided  the  database  used  for  the  sample  selec-
ion.
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Table  1  Perceived  patients  receiving  NSAIDs.a
Perceived  patients  Global  Lisbon  Porto  Coimbra  Faro/Portimão  P
Receiving  NSAIDs  (n  =  503) 38% 38%  36%  40%  40%  nsb
Receiving  NSAIDs  +  gastroprotection  40%  39%  43%  42%  34%  ns
Receiving NSAIDs  aged  ≥  65  years  (n  =  191)  24%  24%  24%  30%  25%  ns
Receiving NSAIDs  aged  ≥  65  years  +  gastroprotection  55%  52%  60%  53%  58%  ns
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aNon-steroidal anti-inﬂammatory drugs.
b Not signiﬁcant.
The  sample  size  (estimated  to  ensure  a  5%  error  mar-
gin  and  a  95%  conﬁdence  interval)  was  300  interviews;  300
randomly  selected  Family  Physicians  from  the  above-cited
regions  were  included,  stratiﬁed  in  a  non-proportional  way,
based  on  the  variable  ‘‘Region’’,  to  ensure  a  minimum  basis
of  30  responders  in  Coimbra  and  in  Faro/Portimão.
Interview  and  questionnaire
The  measuring  tool  used  was  a  non-validated  questionnaire
developed  by  the  authors  of  the  manuscript  on  a  consen-
sus  base  and  consisted  of  open  questions  about  perceived
rates  of  patients’  medications,  complaints,  symptoms  and
gastroprotection  use  and  also  spontaneous  and  pre-speciﬁed
answers  about  knowledge  on  gastrointestinal  risk  factors.
The  questionnaire  was  applied  on  a  personal  interview
basis,  by  well-trained  professionals.  The  questionnaire  was
fulﬁlled  by  the  interviewer  according  to  the  physician’s
answers,  with  mean  interview  duration  of  20  min.  After
three  unsuccessful  phone  contacts,  another  randomized
doctor,  under  the  same  conditions  as  those  used  for  the
remaining  sample,  replaced  the  former  doctor.  Participation
in  the  interview  was  voluntary,  conﬁdential  and  anonymous
and  there  was  no  ﬁnancial  compensation  as  a  result  of  the
participation  in  the  study.  All  variables  analyzed  were  val-
ued  on  their  perceived  existence  or  intention-to-treat  by
the  Family  Physician.  As  this  is  an  observational  study  based
on  the  results  of  a  survey  and  not  a  study  on  human  sub-
jects,  no  formal  approval  from  any  type  of  committee  was
demanded.
Statistical  analysis
A  descriptive  analysis  of  the  results  obtained  was  performed.
For  continuous  variables  the  Student’s  t-test  was  used  and
the  One-way  analysis  of  variance  (ANOVA)  for  the  assessment
of  the  regional  differences.  The  adopted  signiﬁcance  level
was  set  at  0.05.  SPSS  software  v17.0  (Chicago,  IL,  USA)  was
used  for  data  analysis.
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Table  2  Perceived  patients  receiving  ASA.A
Perceived  patients  Global  
Receiving  ASA  (n  =  503)  25%  
Receiving ASA  aged≥  65  years  (n  =  126)  61%  
Receiving ASA  aged≥  65  years  +  gastroprotection  50%  
A Acetylsalicylic acid.
a P < 0.05 when compared to the southern region.esults
nterviews  were  carried  out  between  June  and  July  2007  in
ortugal  (mainland).  To  achieve  the  pretended  300  inter-
iews,  957  Family  Physicians  were  needed  to  contact  by
hone  as  657  (69%)  refused  to  participate.  Three  hundred
nterviews  were  performed,  stratiﬁed  by  region  as  follows:
40  in  the  district  of  Lisbon;  100  in  Porto  and  30  in  Coimbra
nd  Faro/Portimão.  From  the  inquired  physicians,  45%  were
omen,  75%  had  more  than  20  years  of  clinical  practice  and
9%  worked  also  in  emergency  units.
erceived  patients  receiving  non-steroidal
nti-inﬂammatory  drugs  and  acetylsalicylic  acid
ive  hundred  and  three  patients  were,  in  average,  fol-
owed  per  month  per  doctor  with  no  signiﬁcant  differences
y  region.  The  proportion  of  perceived  patients  receiving
SAIDs  was  38%,  from  whom  24%  were  aged  ≥  65  years  old;
rom  this  last  group,  55%  were  receiving  gastroprotective
gents  (Table  1).  Twenty  ﬁve  per  cent  of  perceived  patients
ere  receiving  ASA,  from  which  61%  were  aged  ≥  65  years
ld  (Table  2).
astrointestinal  symptoms  and  impact  in  quality
f life
hysicians  referred  that  around  57%  of  their  patients  had
astrointestinal  symptoms.  In  the  rating  scale  used  (values
anging  from  1  --  never  to  6  --  always),  the  mean  value
btained  was  3.6.  The  main  NSAIDs-related  gastrointestinal
dverse  events  were  dyspepsia  or  gastric  pain  (Table  3).Also  69%  referred  that  gastrointestinal  symptoms  had  a
egative  impact  in  the  quality  of  life  of  their  patients.  In
he  rating  scale  used  (values  ranging  from  1  --  no  impact  to
 --  great  impact)  the  mean  value  obtained  was  4.1.
Lisbon  Porto  Coimbra  Faro/Portimão
26%a 26%a 27%  18%
58%  66%  53%  70%
48%  53%  39%  59%
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Table  3  Identiﬁcation  of  gastrointestinal  symptoms  in  patients  receiving  NSAIDsa or  ASAb with  no  gastroprotection  by  family
physicians.
n  =  299  Always  Often  Sometimes  Few  times  Rarely  Never
Gastric  pain/dyspepsia  3%  28%  41%  17%  10%  1%
Nausea/vomiting  1%  11%  22%  29%  28%  10%
Haemorrhage  1%  0%  5%  18%  49%  27%
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b Acetylsalicylic acid.
harmacologic  prevention  of  gastrointestinal
omplications  in  patients  receiving  non-steroidal
nti-inﬂammatory  drugs
roton  Pump  Inhibitors  (PPIs)  were  the  most  commonly  used
rugs  for  gastroprotection  in  patients  receiving  NSAIDs:  74%
f  the  respondents  referred  that  they  would  always  or  often
se  PPIs  in  their  patients  if  they  were  initiating  a  NSAIDs
herapy,  while  28%  referred  the  use  of  H2-blockers  (Table  4).
isk  factors  and  prevention  of  gastrointestinal
omplications
isk  factors  for  gastrointestinal  complications  identiﬁed  by
he  respondents  are  described  in  Table  5.  All  these  risk  fac-
ors  were  identiﬁed  by  more  than  85%  of  the  respondents,
rst  spontaneously  and  afterwards  by  being  speciﬁcally
sked  about  those  not  previously  reported.  However,  only
n  the  case  of  complicated  peptic  ulcer,  more  than  80%
f  the  respondents  would  always  prescribe  gastroprotec-
ive  agents,  while  the  administration  of  high  doses  or
he  administration  of  two  or  more  NSAIDs  only  motivated
uch  gastroprotection  in  60%  of  the  physicians.  For  the
emaining  risk  factors  identiﬁed  the  gastroprotective  pre-
cription  intention  would  be  only  around  50%  or  even  lower.
For  all  gastrointestinal  risk  factors  identiﬁed,  gastropro-
ection’s  prescription  would  be  used  in  only  47.3%  of  cases
95%  conﬁdence  interval:  45.6--49.0%).
elicobacter  pylori  eradication  in  patients
eceiving  non-steroidal  anti-inﬂammatory  drugshe  presence  of  Helicobacter  pylori  infection  inﬂuenced  78%
f  the  physicians  in  their  decision  for  prescribing  gastropro-
ective  agents;  however,  diagnostic  testing  was  performed
r
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Table  4  Frequency  of  therapeutic  classes  used  for  gastroprotect
n  =  300  Always  Often  S
PPIsc 22%  52%  2
H2-blockers 4%  24%  2
Antacids 0%  7%  1
Prostaglandin  analogues  1%  3%  1
Sucralfate 0%  1%  
a Non-steroidal anti-inﬂammatory drugs.
b Acetylsalicylic acid.
c Proton Pump Inhibitors.n  only  38%  of  cases  mainly  due  to  lack  of  symptoms,
ot  indicated/recommended  and  related  costs.  From  those
ssessing  H.  pylori  status  in  patients  receiving  NSAIDs,  91%
ould  prescribe  eradication  therapy  for  positive  cases.
mportance  of  gastrointestinal  protection
nd national  recommendations
f  the  responding  physicians,  81%  considered  this  as  a  very
mportant  or  extremely  important  matter.  In  the  analogue
cale  used  (ranging  from  1  --  not  important  at  all  to  6  --
xtremely  important),  a  mean  value  of  5.2  was  achieved.
dditionally,  the  existence  of  national  recommendations  on
his  subject  was  deemed  extremely  important  or  very  impor-
ant  by  76%.
iscussion
n  the  published  literature,  gastroprotective  agents’  use
anges  between  7  and  42%  in  patients  receiving  NSAIDs.6--12
n  this  study,  the  perceived  use  of  NSAIDs  referred  by  the
amily  Physicians  in  their  patients  was  high  (38%).  From  the
atients  receiving  NSAIDs,  a  high  proportion  (40%)  was  some-
ow  receiving  gastroprotection  and  this  rate  increased  to
5%  when  only  patients  aged  ≥  65  years  old  were  consid-
red.  Regarding  prescription  of  gastroprotective  agents  to
atients  receiving  ASA  for  cardiovascular  prevention,  given
ts  chronic  use  and  the  older  age  of  most  users,  only  61%  of
atients  receiving  ASA  and  aged  ≥  65  years  old  were  taking
astroprotective  drugs.  Our  result  (40%)  is  higher  than  the
ne  reported  by  Couto  et  al.  (15%)  but  while  our  grade  is  a
esult  of  an  interview  perception  on  an  ‘‘intention-to-treat
asis’’  and  might  be  an  overestimation,  the  other  grade
omes  from  a retrospective  analysis  of  hospital  databases
nvolving  only  admissions  from  NSAIDs  complications  and
ion  in  patients  initiating  a  NSAIDsa or  ASAb therapy.
ometimes  Few  Times  Rarely  Never
0%  3%  1%  2%
2%  15%  24%  11%
4%  21%  33%  26%
4%  18%  31%  34%
4%  2%  2%  1%
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Table  5  Identiﬁcation  of  gastrointestinal  risk  factors  and  proportion  of  family  physicians  always  intended  to  prescribe  gastro-
protective agents.
Risk  factor  Identiﬁcation  Gastroprotection
Peptic  ulcer  with  complications 98% 82%
High  dose  of  NSAIDsa 94%  60%
Administration  of  2  or  more  NSAIDs  90%  60%
Helicobacter  pylori  infection  85%  53%
Age ≥  65  years  old  96%  51%
Corticosteroids  91%  47%
Peptic ulcer  with  no  complications  88%  46%
Dyspepsia 95%  35%
ASAb 87% 34%
Anti-coagulants  86% 30%
Smoking/alcohol  consumption  96%  22%
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b Acetylsalicylic acid.
might  be  an  underestimation  of  the  real  gastroprotection
use.6
Our  results  are  consistent  with  others  in  which  50%  of
the  patients,  ≥  65  years  old  taking  NSAIDs,  were  not  receiv-
ing  gastroprotection8 while  in  patients  treated  with  ASA
only  23%  of  patients  presenting  at  least  one  risk  factor  and
56%  with  a  history  of  complicated  peptic  ulcer  were  receiv-
ing  gastroprotection.13--15 This  low  use  of  gastroprotective
agents  is  in  accordance  with  the  fact  that  the  physicians
only  recalled  haemorrhage  to  occur  always  or  often  in  1%  of
cases,  eventually  due  to  an  inadequate  feedback  from  Ter-
tiary  Care  centres’  reports  on  complications,  but  this  issue
was  not  addressed  in  this  study.  The  low  use  of  gastroprotec-
tive  agents  in  patients  receiving  ASA  may  be  related  to  an
inappropriate  recognition  of  the  gastrointestinal  risks  asso-
ciated  to  this  drug,  either  by  the  patients  or  the  healthcare
professionals  themselves  and  this  is  a  worldwide  problem,
again  eventually  related  to  an  underreporting  feedback  of
complications  from  tertiary  centres  to  the  primary  care
physicians.16,17
This  study  also  shows  that  most  of  the  physicians  inquired
seem  to  be  aware  of  the  gastrointestinal  adverse  effects
associated  to  NSAIDs  use  and  also  seem  to  be  aware  of
the  main  gastrointestinal  risk  factors,  as  most  of  them
were  appropriately  identiﬁed,  spontaneously  or  after  being
speciﬁcally  asked  about.  However,  although  the  risk  is
recognized,  its  magnitude  is  undervalued.  As  result,  the
proportion  of  physicians  that  would  always  prescribe  gas-
troprotective  agents  to  patients  with  gastrointestinal  risk
factors  is  low,  except  for  patients  with  previous  history  of
complicated  peptic  ulcer,  achieving  82%.  Our  results  suggest
that  more  than  half  of  the  patients  receiving  NSAIDs  with
indication  for  gastroprotection  (presence  of  one  or  more
risk  factors),  would  not  receive  it.  These  results  reveal  an
incomplete  compliance  with  the  existing  clinical  practice
recommendations.5,15,18--23
Several  observational  studies  carried  out  within  the  scope
of  Primary  Care,  with  a  different  methodology  compared  to
the  one  used  in  this  study,  have  conﬁrmed  this  low  use  of
gastroprotection  strategies  in  patients  receiving  NSAIDs  with
gastrointestinal  risk  factors  with  prescription  rates  of  only
10--39%  in  patients  with  at  least  one  risk  factor.10,11,24--27
t
b
t
oConcerning  the  use  of  gastroprotective  medicines,
lthough  PPIs  were  the  most  efﬁcient  and  commonly
sed  drugs,  28%  of  the  respondents  always  or  often  used
2-blockers,  even  though  at  the  time  the  study  was  con-
ucted,  the  use  of  these  drugs  was  already  considered
nappropriate.15,19 This  use  of  a  less  efﬁcient  drug  might  be
xplained  by  the  fact  that,  still  in  recent  national  recom-
endations,  its  use  is  suggested  as  an  alternative  to  PPI  with
o  explanation  on  the  different  efﬁciency  rates  and  safety
roﬁles.28 Also,  although  85%  of  the  Family  Physicians  rec-
gnized  H.  pylori  infection  as  a  gastrointestinal  risk  factor,
2%  did  not  screened  for  the  infection  in  patients  receiving
SAIDs  in  clinical  practice.
The  Maastricht  Consensus  as  well  as  consensus  state-
ents  issued  by  other  professional  organizations  recom-
end  both  screening  and  eradication  therapy  for  positive
ases,  before  initiating  long-term  treatment  with  NSAIDs
nd  for  patients  on  NSAIDs  therapy  who  developed  gastro-
uodenal  ulcers.29--31 These  guidelines  also  establish  that
n  NSAIDs  chronic  users  with  high  gastrointestinal  risk  (his-
ory  of  complicated  peptic  ulcer),  eradication  therapy  alone
s  not  enough  to  prevent  recurrences  of  gastrointestinal
omplications;  therefore,  an  additional  maintenance  ther-
py  with  PPIs  is  necessary.  The  complexity  of  this  subject
nd  the  continuous  information  update  on  the  infection
pproach  in  patients  receiving  NSAIDs  may  have  inﬂuenced
he  answers  of  the  physicians.19
The  main  limitation  of  this  study  is  that  all  answers  are
ased  on  the  physicians’  perception  and  intention-to-treat
ather  than  on  their  own  clinical  practice  records  and  this
act  might  result  in  an  overestimation  of  the  real  gastro-
rotection  use.  Only  a  prospective  study  could  produce  a
ore  realistic  estimation  of  the  Family  Physicians’  prescrip-
ion  proﬁle.  Nevertheless  the  observed  consistency  across
he  different  regions  provides  some  internal  validation
f  the  results  and  the  sample  size  gives  us  a narrow  conﬁ-
ence  interval  to  allow  some  conﬁdence  on  the  results
btained.  Another  limitation  was  the  random  sample  selec-
ion  by  phone  contact,  which  is  inﬂuenced  by  the  availability
oth  of  the  telephone  line  and  of  the  respondent.  In  addi-
ion  a  relatively  high  participation  refusal  rate  (69%)  was
bserved  and  the  database  used  does  not  provide  us  with  the
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148  
emographic  features  of  the  physicians  included,  preventing
s  from  establishing  a  comparison  between  respondents  and
on-respondents.  This  might  have  resulted  in  more  answers
rom  Family  Physicians  more  aware  of  the  problem  and,
gain,  bias  the  results  in  favour  of  better  gastroprotection
ates.  A  potential  inquirer-related  bias  was  minimized  by  a
areful  selection  and  training  of  the  inquirers  and  a  close
upervision  of  the  ﬁeldwork.
The  results  of  this  study  allow  us  to  say  that  clinical  rec-
mmendations  on  gastrointestinal  protection  are  not  fully
mplemented  and  that  this  is  an  area  that  should  be  more
alued.  In  this  study,  the  Family  Physicians  conﬁrm  the
eed  to  elaborate  national  clinical  recommendations  on  this
opic.  A  full  collaboration  between  Family  Physicians  and
astroenterology  Societies  in  promoting  joined  updates  by
onferences  or  lectures  in  their  national  meetings,  showing
he  two  perspectives  of  the  same  problem,  could  be  a  nice
ay  to  improve  better  implementation  of  gastroprotection
se.
onclusions
n  conclusion,  we  found  that  although  most  of  the  inquired
amily  Physicians  were  aware  of  NSAIDs  induced  gastroin-
estinal  toxicity  and  were  able  to  appropriately  identify  the
ain  gastrointestinal  risk  factors,  the  risk  magnitude  esti-
ate  seemed  to  be  inappropriate,  since  Family  Physicians
ould  not  prescribe  gastrointestinal  protective  agents  in
ore  than  half  the  patients  with  associated  gastrointestinal
isk  factors.
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